Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 14Endometrial Neoplasms 11Ovarian Neoplasms 10Pancreatic Neoplasms 9Stomach Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 6Prostatic Neoplasms 6Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Lung Neoplasms 5Esophageal Neoplasms 5Neoplasms 4Breast Neoplasms, Male 4Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Gallbladder Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2Urethral Neoplasms 2

Interventions

tucatinib 1niraparib 1abemaciclib 1Trastuzumab 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Trastuzumab × Gynecologic × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡